Allergan Inc. Chief Executive David Pyott saw a big payday in 2006, a year in which he oversaw a major acquisition that boosted the Irvine company in medical cosmetics.
Pyott saw total compensation of $12 million last year, according to an Allergan filing with the Securities and Exchange Commission and an Associated Press report.
The bulk of the payment, $8.7 million, came from stock and option grants.
Pyott was paid $1.2 million in salary, $2 million in non-stock bonuses and $46,482 in other compensation, including $20,500 in a tax and financial planning allowance and a $10,500 auto and gas allowance.
Allergan had sales of $3 billion last year. The company had a net loss of $127.4 million and made $547.2 million after adjusting for acquisition and restructuring costs.
Its market value is $17 billion.
In early 2006, Pyott oversaw the $3.2 billion buy of Santa Barbara’s Inamed Corp., which added a wrinkle smoother, breast implants and an obesity treatment to Allergan’s cosmetic products, led by Botox.
